BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF
t: +44 (0) 115 8880 406f: +44 (0) 115 8229345

Welcome to Park Grove IP

Park Grove IP is a patent attorney firm that provides expert advice to companies in the chemical, pharmaceutical and life sciences fields.

The ambition of Park Grove IP is straightforward – to help its clients’ businesses to succeed and to grow as a result of that success. To achieve this goal, the aim of Park Grove IP is to identify, optimise and deliver an intellectual property strategy that is individually tailored to each client’s needs, and also to provide high quality advice in a prompt and cost-effective manner.

Please contact us to find out how we can help you with your intellectual property needs.

Our Latest News

What is the term of a European patent?

Authors: Mike Snodin and Jim Boff
CIPA Journal (July 2016)

This article, which was first published in the July 2016 edition of the CIPA Journal, explains the numerous reasons why the term af... Read More

Difficult Questions, Important Answers: The Latest Case on SPCs

Author: Mike Snodin
SCRIP Regulatory Affairs (1 February 2016)

This article, first published in SCRIP Regulatory Affairs on 1 February 2016, discusses the latest case on SPCs (C-572/15, F. H... Read More

The CJEU Calls Extra Time For SPCs - But There May Be Further Battles Ahead For Companies

Author: Mike Snodin
SCRIP Regulatory Affairs (23 October 2015)

This article, which was first published in SCRIP Regulatory Affairs on 23 October 2015, discusses the CJEU's judgement in ... Read More

Europe is now poised to award longer terms to some SPCs

News & Views
Author: Mike Snodin

On 10 September 2015, Advocate-General (A-G) Jääskinen of The Court of Justice of the European Union (CJEU) issued his opinion in a case (C-471... Read More

A landmark case for second medical use patents in the UK

News & Views
Author: Mike Snodin

On 28 May 2015, the UK Court of Appeal issued its judgement in an appeal by Warner-Lambert against a decision of the UK High Court that refused to grant ... Read More

When public policies collide: the battle to enforce second medical use patents for drugs in Europe

Author: Mike Snodin
SCRIP Regulatory Affairs (24 March 2015)

This article discusses very important judgements from courts in the UK and the Netherlands that are the first to address the issu... Read More

The Court of Justice clarifies certain provisions governing parallel importation

News & Views
Author: Mike Snodin

On 12 February 2015, the Court of Justice (CJEU) handed down its judgement in Merck Canada, Merck Sharp & Dohme v Sigma Pharmaceuticals (C-539/13). ... Read More

The European Commission submits its views in an important case for SPCs to biologics

News & Views
Author: Mike Snodin

Pharmaq v Intervet (E-16/14) is a case being heard by the EFTA Court that is potentially of huge importance to those seeking (or holding) supplementary p... Read More

Supplementary Protection Certificates: the Court of Justice of the EU will have its day after all

Author: Mike Snodin
SCRIP Regulatory Affairs (22 December 2014)

This article, which was first published by SCRIP Regulatory Affairs on 22 December 2014, reports that the Court of Justice o... Read More

Supplementary Protection Certificates: the never-ending saga of Article 3(a)

Author: Mike Snodin
SCRIP Regulatory Affairs (1 December 2014)

This article, which was first published by SCRIP Regulatory Affairs on 1 December 2014, explains why the ruling of the UK High... Read More

The CJEU – for supplementary protection certificates, who needs it?

Author: Mike Snodin
SCRIP Regulatory Affairs (24 October 2014)

This article, which was first published by SCRIP Regulatory Affairs on 24 October 2014, explains why patent offices in Europe d... Read More

Every cloud has a silver lining: Portugal's loss may be the UK's gain

Author: Mike Snodin
SCRIP Regulatory Affairs (June 2014)

This article appeared in the June 2014 edition of SCRIP Regulatory Affairs. It discusses the CJEU's ruling in case C-555/13 (M... Read More

Three CJEU decisions that answer some questions but pose many more

Journal of Intellectual Property Law & Practice (2014) 9 (7): 599-604
Author: Mike Snodin

This article first appeared online on 22 April 2014 in the Journal of Intellectual Property Law ... Read More

You can count on us: UK IPO agrees to award longer term to some SPCs

SCRIP Regulatory Affairs December 2013, 15
Author: Mike Snodin

This article appeared in the December 2013 edition of SCRIP Regulatory Affairs. It reports the outcome of a case that Mike arg... Read More

Neurim wins the battle but not (yet) the war for innovators

SCRIP Regulatory Affairs September 2012, 14-15
Authors: Mike Snodin and Michael Pears

This article appeared in the September 2012 edition of SCRIP Regulatory Affairs. It explains the positi... Read More

A brave new world for supplementary protection certificates?

Life Sciences Intellectual Property Review 2012
Authors: Mike Snodin and Michael Pears

This article appeared in the 2012 edition of Life Sciences Intellectual Property Review. It discusses ... Read More

Novartis decision completes a new model for SPCs in EU

SCRIP Regulatory Affairs April 2012, 5
Authors: Mike Snodin and Michael Pears

This article appeared in the April 2012 edition of SCRIP Regulatory Affairs. It reports the decision in the Nov... Read More

Master the detail to get the most from SPCs

Business Development & Licensing Journal (2012) 17 (April): 10-13
Author: Mike Snodin

This article appeared in the April 2012 edition of Business Development & Licensing Journal. It... Read More

Supplementary protection certificates: The CJEU issues its decision in two seminal cases

Bio-Science Law Review (2012) 12 (2): 58-62
Authors: Mike Snodin, John Miles and Michael Pears

This article appeared in the January 2012 edition of Bio-Science Law Review. It discusses the ... Read More

European court ruling on SPCs brings relief to industry

SCRIP Regulatory Affairs January 2012, 7-8
Author: Mike Snodin

This article appeared in the January 2012 edition of SCRIP Regulatory Affairs. It discusses the decision of the Court of Justi... Read More

Every day counts: why pharmaceutical companies in the EU need to make sure they get the right SPC term

SCRIP Regulatory Affairs October 2011, 6-7
Author: Mike Snodin

This article appeared in the October 2011 edition of SCRIP Regulatory Affairs. It argues that the standard practice of many na... Read More

Supplementary protection certificates: is a new era beckoning for combination drugs in the EU?

SCRIP Regulatory Affairs August 2011, 8-9
Authors: Michael Pears and Mike Snodin

This article appeared in the August 2011 edition of SCRIP Regulatory Affairs. It discusses Advocate-General ... Read More

Hopes rise for a bright future for paediatric SPC extensions in the EU

SCRIP Regulatory Affairs August 2011, 7-8
Author: Mike Snodin

This article appeared in the August 2011 edition of SCRIP Regulatory Affairs. It reports that Advocate-General Yves Bot of the ... Read More

Making the Most of Paediatric SPC Extensions

Regulatory Affairs Journal, Pharma, June 2008, 387-388
Authors: Mike Snodin and John Miles

This article appeared in the June 2008 edition of Regulatory Affairs Journal, Pharma. Following o... Read More

Making the Most of Paediatric SPC Extensions

Regulatory Affairs Journal, Pharma, July 2007, 459-463
Authors: Mike Snodin and John Miles

This article appeared in the July 2007 edition of Regulatory Affairs Journal, Pharma. It is the fi... Read More

Cookies & Privacy

We Use Cookies To Improve User Experience. If You Continue Without Changing Settings We Will Assume You Are Happy To Receive Cookies

Disable Cookies
Privacy & Cookies | Terms & Conditions